Given that COVID-19 comorbidity patients are more susceptible to secondary infections and release LPS with its complications, it is worth noting that lactoferrin has a unique competitive binding to LPS and LPS-binding (CD14) receptors, and can directly suppress cytokine production through inhibition of NFkB binding to the cytokine promoter region (Sakamoto et al., 2006; Yang et al., 2020). The gene discussed is LTF; the disease is infection.